9.305USD+0.81%Mkt Cap: 1.21B USDP/E: —Last update: 2026-05-26
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clin…
Industry Peers
Diagnostics & Research166.94BUSDP/E 24.7
122.72BUSDP/E 33.6
44.05BUSDP/E 41.1
34.33BCHFP/E 37.8
33.46BUSDP/E 43.3
32.69BUSDP/E 25.5
28.46BUSD—
27.28BUSDP/E 20.3
Indicators:|
Key Statistics
Company
Market Cap1.21B USD
Enterprise Value1.45B USD
Revenue (TTM)745.97M USD
Gross Profit314.29M USD
Net Income (TTM)-108.03M USD
Revenue/Share5.803 USD
Last Price9.305 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)24.99
PEG2.09
EV/EBITDA339.49
EV/Revenue1.94
P/S1.59
P/B1.40
EPS (TTM)-0.79
EPS (Forward)0.36
52W Range
4.72051% of range13.74
52W High13.74 USD
52W Low4.720 USD
Profitability
Gross Margin43.21%
Oper. Margin-9.34%
EBITDA Margin0.57%
Profit Margin-14.85%
ROE-12.91%
ROA-7.94%
Growth
Revenue Growth11.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF5.23M USD
CapEx (TTM)27.01M USD
FCF Margin4.45%
FCF Yield2.73%
Net Debt262.39M USD
Net Debt/EBITDA61.49
Balance Sheet
Debt/Equity0.49
Current Ratio4.42
Quick Ratio3.71
Book Value/Sh6.486 USD
Cash/Share1.122 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)15.06 USD
Target Range11.00 USD – 25.00 USD
# Analysts9
Ownership
Shares Out.130.21M
Float118.45M
Insiders1.93%
Institutions108.56%
Short Interest
Short Ratio3.8d
Short % Float8.63%
Short % Out.7.33%
Shares Short9.54M
Short (prev mo.)7.61M
Technical
SMA 508.294 (+12.2%)
SMA 2009.611 (-3.2%)
Beta1.80
S&P 52W Chg28.31%
Avg Vol (30d)2.22M
Avg Vol (10d)1.42M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—